Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 1;21(13):4709.
doi: 10.3390/ijms21134709.

Pharmacogenomics of Hypertension Treatment

Jacek Rysz  1 , Beata Franczyk  1 , Magdalena Rysz-Górzyńska  2 , Anna Gluba-Brzózka  1
Affiliations
Review

Pharmacogenomics of Hypertension Treatment

Jacek Rysz et al. Int J Mol Sci. .

Abstract

Hypertension is one of the strongest modifiable cardiovascular risk factors, affecting an increasing number of people worldwide. Apart from poor medication adherence, the low efficacy of some therapies could also be related to inter-individual genetic variability. Genetic studies of families revealed that heritability accounts for 30% to 50% of inter-individual variation in blood pressure (BP). Genetic factors not only affect blood pressure (BP) elevation but also contribute to inter-individual variability in response to antihypertensive treatment. This article reviews the recent pharmacogenomics literature concerning the key classes of antihypertensive drugs currently in use (i.e., diuretics, β-blockers, ACE inhibitors, ARB, and CCB). Due to the numerous studies on this topic and the sometimes-contradictory results within them, the presented data are limited to several selected SNPs that alter drug response. Genetic polymorphisms can influence drug responses through genes engaged in the pathogenesis of hypertension that are able to modify the effects of drugs, modifications in drug-gene mechanistic interactions, polymorphisms within drug-metabolizing enzymes, genes related to drug transporters, and genes participating in complex cascades and metabolic reactions. The results of numerous studies confirm that genotype-based antihypertension therapies are the most effective and may help to avoid the occurrence of major adverse events, as well as decrease the costs of treatment. However, the genetic heritability of drug response phenotypes seems to remain hidden in multigenic and multifactorial complex traits. Therefore, further studies are required to analyze all associations and formulate final genome-based treatment recommendations.

Keywords: ACE inhibitors; angiotensin II receptor blockers; calcium channel blocking (CCB) agents; diuretics; pharmacogenetics; polymorphisms; response to drugs.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mechanism of calcium channel blockers’ (CCBs) action.
Figure 2
Figure 2
Mechanisms of action of angiotensin-II receptor blockers and angiotensin-converting enzyme inhibitors.
Figure 3
Figure 3
Effects of action of β-blockers.
Figure 4
Figure 4
Effects of action of thiazide diuretics.
See this image and copyright information in PMC

References

    1. Oliveira-Paula G.H., Pereira S.C., Tanus-Santos J.E., Lacchini R. Pharmacogenomics and Hypertension: Current Insights. Pharmgenomics Pers. Med. 2019;12:341–359. doi: 10.2147/PGPM.S230201. - DOI - PMC - PubMed
    1. Heart Disease and Stroke Statistics—2019 Update. [(accessed on 15 February 2020)]; Available online: https://professional.heart.org/professional/ScienceNews/UCM_503383_Heart....
    1. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005;365:217–223. doi: 10.1016/S0140-6736(05)17741-1. - DOI - PubMed
    1. Torrellas C., Carril J.C., Cacabelos R. Benefits of Pharmacogenetics in the Management of Hypertension. J. Pharmacogenomics Pharmacoproteomics. 2014;5:126. doi: 10.4172/2153-0645.1000126. - DOI
    1. Yoon S.S., Burt V., Louis T., Carroll M.D. Hypertension among adults in the United States; 2009–2010. NCHS Data Brief. 2012;107:1–7. - PubMed

MeSH terms

Substances